Sorry to but in to your discussion but just a couple of thoughts. InterMune (a while back) created an early access program for Pirfenidone where a lottery system was used as the entry criteria. Also Actimmune was available (granted off-label) while the company was actively recruiting for the (since discontinued) INSPIRE study. One motivation to enroll in a trial rather then CU program could be the drug is provided free of charge for some period after the study. Yeah I guess it slows enrollment somewhat but there is still incentive for some and you get some of the benefits of getting the drug out there. Just my 2 cents.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.